Today's edition of Market Checkup focuses on EU drug approvals for struggling biotech Dendreon and big pharma company Sanofi, and a controversial dividend stock to watch.
Note: At 6:38, the speaker incorrectly states that Sanofi had a partnership with biotech company Rigel. The Fool regrets the error.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.